Christopher Raymond
Stock Analyst at Piper Sandler
(2.50)
# 2,385
Out of 4,915 analysts
132
Total ratings
50.46%
Success rate
-1.17%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $72.07 | -2.87% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $132.08 | -12.93% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.52 | +1,632.77% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $58.14 | +116.74% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.99 | +101.01% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $4.33 | +84.76% | 8 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $462.27 | +15.30% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $556.76 | +81.95% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $28.45 | +392.18% | 5 | Jan 13, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $72 | $40.71 | +76.86% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $195.15 | +12.74% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.54 | +746.91% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $3.95 | +1,798.73% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $14.85 | +411.78% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $2.19 | +356.62% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $10.38 | +217.92% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.63 | +166.16% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $11.40 | +92.98% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $3.72 | +7.67% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $7.67 | +225.95% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $296.96 | -3.02% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $34.87 | +17.58% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $47.11 | -40.56% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $77.80 | -48.59% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $6.88 | +1,209.09% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.44 | +6,589.90% | 2 | Mar 13, 2020 |
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $72.07
Upside: -2.87%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $132.08
Upside: -12.93%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.52
Upside: +1,632.77%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $58.14
Upside: +116.74%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.99
Upside: +101.01%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $4.33
Upside: +84.76%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $462.27
Upside: +15.30%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $556.76
Upside: +81.95%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $28.45
Upside: +392.18%
Monopar Therapeutics
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $40.71
Upside: +76.86%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $195.15
Upside: +12.74%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.54
Upside: +746.91%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $3.95
Upside: +1,798.73%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $14.85
Upside: +411.78%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $2.19
Upside: +356.62%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $10.38
Upside: +217.92%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.63
Upside: +166.16%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $11.40
Upside: +92.98%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $3.72
Upside: +7.67%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $7.67
Upside: +225.95%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $296.96
Upside: -3.02%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $34.87
Upside: +17.58%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $47.11
Upside: -40.56%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $77.80
Upside: -48.59%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $6.88
Upside: +1,209.09%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.44
Upside: +6,589.90%